金水宝片联合异丙托溴铵治疗慢性支气管炎的临床研究

目的 探讨金水宝片联合异丙托溴铵治疗慢性支气管炎的临床疗效。方法 选取2021年1月—2023年11月内蒙古医科大学附属医院收治的慢性支气管炎患者106例，随机分为对照组（53例）和治疗组（53例）。对照组雾化吸入吸入用异丙托溴铵溶液，2 mL/次，2次/d。在此基础上，治疗组口服金水宝片，4片/次，3次/d。两组患者治疗3个月。观察两组患者临床疗效，比较治疗前后两组患者主症消失时间，肺功能指标用力肺活量（FVC）、呼气峰值流量（PEF）和最大呼气中段流量（MMEF）水平，外周血T淋巴细胞亚群水平，及血清嗜酸性粒细胞趋化因子（Eotaxin）、肿瘤坏死因子-α（TNF-α）、转化生长因子-β1（TGF-β1）和内皮素-1（ET-1）水平。结果 治疗后，治疗组临床总有效率为96.23%，明显高于对照组的84.91%（P＜0.05）。治疗后，治疗组各项主症的消失时间均明显短于对照组（P＜0.05）。治疗后，两组患者FVC、PEF、MMEF、CD3^＋、CD4^＋和CD4^＋/CD8^＋水平明显高于治疗前，而CD8^＋、Eotaxin、TNF-α、TGF-β1和ET-1水平显著低于治疗前（P＜0.05），且治疗后治疗组患者肺功能指标、外周血T淋巴细胞亚群水平和血清因子水平明显好于对照组（P＜0.05）。结论 金水宝片联合异丙托溴铵治疗慢性支气管炎可加速患者症状缓解，提高肺功能及临床疗效，改善免疫功能及炎症状态。

Clinical study on Jinshuibao Tablets combined with and ipratropium bromide in treatment of chronic bronchitis

Objective To explore the clinical efficacy of Jinshuibao Tablets combined with and ipratropium bromide in treatment of chronic bronchitis. Methods Patients (106 cases) with chronic bronchitis in the Affiliated Hospital of Inner Mongolia Medical University from January 2021 to November 2023 were randomly divided into control (53 cases) and treatment (53 cases) group. Patients in the control group were atomization inhalation administered with Ipratropium Bromide Solution for Inhalation, 2 mL/time, twice daily. Patients in the treatment group were po administered with Jinshuibao Tablets on the basis of the control group, 4 tablets/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical evaluations were evaluated, the disappearance time of main symptoms, lung function indicators FVC, PEF and MMEF, T lymphocyte subsets levels of peripheral blood, and the levels of serum Eotaxin, TNF-α, TGF-β1 and ET-1 in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was 96.23%, which was significantly higher than that of the control group (84.91%, P < 0.05). After treatment, the disappearance time of the main symptoms in the treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, the levels of FVC, PEF, MMEF, CD3^＋, CD4^＋ and CD4^＋/CD8^＋ in two groups were significantly higher than those before treatment, while the levels of CD8^＋, Eotaxin, TNF-α, TGF-β1 and ET-1 were significantly lower than those before treatment (P < 0.05), and the pulmonary function indexes, peripheral blood T lymphocyte subsets and serum factor levels in the treatment group were significantly better than those in the control group (P < 0.05). Conclusion Jinshuibao Tablets combined with ipratropium bromide in treatment of chronic bronchitis can accelerate the relief of symptoms, improve lung function and clinical efficacy and immune function and inflammatory state.